Associations Between Specialized Dementia Care, COVID-19 and Central Nervous System Medication Use in Assisted Living: a Population-based Repeated Cross-sectional Study

Overview

Journal BMC Geriatr

Publisher Biomed Central

Specialty Geriatrics

Date 2024 Aug 14

PMID 39143530

Authors

Colleen J Maxwell

Hana Dampf

Jillian P Squires

David B Hogan

Cecilia A Cotton

Erik Youngson MMath

Zoe Hsu

Matthias Hoben

Affiliations

Soon will be listed here.

Abstract

Background: Assisted living (AL) is an increasingly common residential setting for persons with dementia; yet concerns exist about sub-optimal care of this population in AL given its lower levels of staffing and services. Our objectives were to (i) examine associations between AL setting (dementia care vs. other), COVID-19 pandemic waves, and prevalent antipsychotic, antidepressant, anti-dementia, benzodiazepine, and anticonvulsant drug use among residents with dementia/cognitive impairment, and (ii) explore associations between resident and home characteristics and prevalent medication use.

Methods: We conducted a population-based, repeated cross-sectional study using linked clinical and health administrative databases for all publicly funded AL homes in Alberta, Canada, examined between January 2018 - December 2021. The quarterly proportion of residents dispensed a study medication was examined for each setting and period (pandemic vs. comparable historical [2018/2019 combined]) focusing on four pandemic waves (March-May 2020, September 2020-February 2021, March-May 2021, September-December 2021). Log-binomial GEE models estimated prevalence ratios (PR) for period (pandemic vs. historical periods), setting (dementia care vs. other) and period-setting interactions, adjusting for resident (age, sex) and home (COVID-19 cases, health region, ownership) characteristics.

Results: On March 1, 2020, there were 2,779 dementia care and 3,013 other AL residents (mean age 83, 69% female) with dementia/cognitive impairment. Antipsychotic use increased during waves 2-4 in both settings, but this was more pronounced in dementia care than other AL during waves 3 and 4 (e.g., adjusted [adj]PR 1.20, 95% CI 1.14-1.27 vs. adjPR 1.09, 95% CI 1.02-1.17, interaction p = 0.023, wave 3). Both settings showed a statistically significant but modest increase in antidepressant use and decrease in benzodiazepine use. For dementia care AL residents only, there was a statistically significant increase in gabapentinoid use during several waves (e.g., adjPR 1.32, 95% CI 1.10-1.59, wave 3). Other than a modest decrease in prevalent anti-dementia drug use for both settings in wave 2, no other significant pandemic effects were observed.

Conclusions: The persistence of the pandemic-associated increase in antipsychotic and antidepressant use in AL residents coupled with a greater increase in antipsychotic and gabapentinoid use for dementia care settings raises concerns about the attendant risks for residents with cognitive impairment.

References

. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023; 71(7):2052-2081. DOI: 10.1111/jgs.18372. View

Maxwell C, Campitelli M, Hogan D, Diong C, Austin P, Amuah J . Relevance of frailty to mortality associated with the use of antipsychotics among community-residing older adults with impaired cognition. Pharmacoepidemiol Drug Saf. 2018; 27(3):289-298. DOI: 10.1002/pds.4385. View

Austin P . Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28(25):3083-107. PMC: 3472075. DOI: 10.1002/sim.3697. View

Hoben M, Li W, Dampf H, Hogan D, Corbett K, Chamberlain S . Caregiver Involvement and Concerns with Care of Residents of Assisted Living before and during the COVID-19 Pandemic. Gerontology. 2023; 69(7):839-851. DOI: 10.1159/000530622. View

Maxwell C, Soo A, Hogan D, Wodchis W, Gilbart E, Amuah J . Predictors of Nursing Home Placement from Assisted Living Settings in Canada. Can J Aging. 2013; 32(4):333-48. DOI: 10.1017/S0714980813000469. View

Candon M, Strominger J, Gerlach L, Maust D . Antiepileptic prescribing to persons living with dementia residing in nursing homes: A tale of two indications. J Am Geriatr Soc. 2022; 71(1):89-97. PMC: 9870979. DOI: 10.1111/jgs.18119. View

Stall N, Zipursky J, Rangrej J, Jones A, Costa A, Hillmer M . Assessment of Psychotropic Drug Prescribing Among Nursing Home Residents in Ontario, Canada, During the COVID-19 Pandemic. JAMA Intern Med. 2021; 181(6):861-863. PMC: 7961468. DOI: 10.1001/jamainternmed.2021.0224. View

Zimmerman S, Scales K, Wiggins B, Cohen L, Sloane P . Addressing Antipsychotic Use in Assisted Living Residents with Dementia. J Am Geriatr Soc. 2015; 63(9):1970-1. DOI: 10.1111/jgs.13625. View

Rogers P, Stoner J . Modification of the Sandwich Estimator in Generalized Estimating Equations with Correlated Binary Outcomes in Rare Event and Small Sample Settings. Am J Appl Math Stat. 2016; 3(6):243-251. PMC: 4793734. DOI: 10.12691/ajams-3-6-5. View

10.

Hogan D, Maxwell C, Fung T, Ebly E . Regional variation in the use of medications by older Canadians--a persistent and incompletely understood phenomena. Pharmacoepidemiol Drug Saf. 2003; 12(7):575-82. DOI: 10.1002/pds.803. View

11.

Maxwell C, Dampf H, Alkabbani W, Cotton C, Gamble J, Hogan D . Psychotropic, Anticonvulsant, and Opioid Use in Assisted Living Residents Before and During the COVID-19 Pandemic. J Am Med Dir Assoc. 2023; 25(1):121-129. DOI: 10.1016/j.jamda.2023.09.009. View

12.

Maclagan L, Bronskill S, Guan J, Campitelli M, Herrmann N, Lapane K . Predictors of Cholinesterase Discontinuation during the First Year after Nursing Home Admission. J Am Med Dir Assoc. 2018; 19(11):959-966.e4. DOI: 10.1016/j.jamda.2018.07.020. View

13.

Campitelli M, Bronskill S, Maclagan L, Harris D, Cotton C, Tadrous M . Comparison of Medication Prescribing Before and After the COVID-19 Pandemic Among Nursing Home Residents in Ontario, Canada. JAMA Netw Open. 2021; 4(8):e2118441. PMC: 8329744. DOI: 10.1001/jamanetworkopen.2021.18441. View

14.

Maxwell C, Amuah J, Hogan D, Cepoiu-Martin M, Gruneir A, Patten S . Elevated Hospitalization Risk of Assisted Living Residents With Dementia in Alberta, Canada. J Am Med Dir Assoc. 2015; 16(7):568-77. DOI: 10.1016/j.jamda.2015.01.079. View

15.

Supasitthumrong T, Bolea-Alamanac B, Asmer S, Woo V, Abdool P, Davies S . Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report. Br J Clin Pharmacol. 2018; 85(4):690-703. PMC: 6422659. DOI: 10.1111/bcp.13844. View

16.

Zaki N, Brakoulias V . The impact of COVID-19 on benzodiazepine usage in psychiatric inpatient units. Australas Psychiatry. 2022; 30(3):334-337. PMC: 8841396. DOI: 10.1177/10398562211059090. View

17.

Candon M, Strominger J, Gotlieb E, Maust D . Nursing Home Characteristics Associated with High and Low Levels of Antipsychotic, Benzodiazepine, and Opioid Prescribing to Residents with Alzheimer's Disease and Related Dementias: A Cross-Sectional Analysis. J Am Med Dir Assoc. 2022; 23(11):1780-1786.e2. PMC: 9637710. DOI: 10.1016/j.jamda.2022.05.025. View

18.

Wastesson J, Fritzell J, Burstrom B, Johnell K, Fastbom J . Regional variations in excessive polypharmacy and potentially inappropriate drug use among older adults in Sweden: Trends from 2006 to 2020. Front Pharmacol. 2023; 14:1030849. PMC: 9945538. DOI: 10.3389/fphar.2023.1030849. View

19.

Watt J, Goodarzi Z, Veroniki A, Nincic V, Khan P, Ghassemi M . Comparative Efficacy of Interventions for Aggressive and Agitated Behaviors in Dementia: A Systematic Review and Network Meta-analysis. Ann Intern Med. 2019; 171(9):633-642. DOI: 10.7326/M19-0993. View

20.

Resnick B, Kolanowski A, Van Haitsma K, Galik E, Boltz M, Ellis J . Current Psychotropic Medication Use and Contributing Factors Among Nursing Home Residents With Cognitive Impairment. Clin Nurs Res. 2019; 30(1):59-69. PMC: 6776729. DOI: 10.1177/1054773819838678. View